

Ammonia and Endogenous Benzodiazepine-like Compounds in the Pathogenesis of Hepatic Encephalopathy

I. Venturini, L. Corsi, R. Avallone, F. Farina, G. Bedogni, C. Baraldi, M. Baraldi & M. L. Zeneroli

Dipartimento di Medicina Interna, Ospedale di Susa, Torino, Italy; Cattedra di Semeiotica e Metodologia Medica, Università di Modena e Reggio Emilia, Italy; Dipartimento di Scienze Farmaceutiche, Università di Modena e Reggio Emilia, Italy

Venturini I, Corsi L, Avallone R, Farina F, Bedogni G, Baraldi C, Baraldi M, Zeneroli ML. Ammonia and endogenous benzodiazepine-like compounds in the pathogenesis of hepatic encephalopathy. *Scand J Gastroenterol* 2001;36:423–425.

Background: Ammonia and endogenous benzodiazepines (BDZs) are two of the most important agents among those taken into consideration in the pathogenesis of hepatic encephalopathy (HE). **Methods:** Venous ammonia and endogenous BDZs sera levels were assayed in 58 liver cirrhosis patients (34 male, 24 female) free of commercial BDZs. Endogenous BDZs were measured by binding assay after high-performance liquid chromatography purification. Ammonia was assessed by colorimetric test. **Results:** Endogenous BDZs and ammonia were significantly higher in Child-Pugh class C than in class B and class A ($P < 0.05$), correlating to the severity of the liver dysfunction but not with the degree of HE. A significant difference, in fact, was noted between degree 0 (no HE) versus III–IV of HE ($P < 0.05$), but not between degrees I–II versus III–IV. Regression analysis performed to find a correlation between the ammonia and BDZ levels in HE resulted negative. **Conclusion:** Clinical evidence is provided in cirrhotic patients that ammonia and endogenous BDZ levels do not correlate with each other in the outcome of HE.

Key words: Ammonia; endogenous benzodiazepines; hepatic encephalopathy

Maria Luisa Zeneroli, *Cattedra di Semeiotica e Metodologia Medica, Dipartimento di Medicina Interna, Università di Modena, Via del Pozzo 71–41100 Modena, Italy (fax. +39 59424363; e-mail. zeneroli@unimo.it)*

Hepatic encephalopathy (HE) is a complex neuropsychiatric disorder secondary to acute or chronic liver failure characterized by an impairment of the central nervous system. Two important factors of the syndrome are the increased tone of the inhibitory γ -aminobutyric acid (GABA) receptor system and the elevated levels of ammonia (1, 2). Endogenous benzodiazepine-like compounds (BZDs) that are positive allosteric modulators of GABA_A receptors, have been proposed as contributing factors (3). An increased presence of BZDs has, in fact, been found in the brain and in the blood of animals (4) and patients with HE (5, 6) owing to fulminant hepatic failure (FHF) or to liver cirrhosis (7) when compared with normal subjects. These compounds seem to be increased in 60% of cases of HE. However, the weak correlation between the levels of BZDs and the degree of HE due to FHF suggests a potential role of these compounds only in the neuronal dysfunction, which characterizes HE (8). Further evidence for the possible involvement of BZDs in the development of HE derives from clinical studies, where a selective BZD antagonist has been shown to rapidly improve HE in responding patients (5, 9, 10), working as a symptomatic drug. Evidence in the mechanism that enhances GABAergic neurotransmission

during HE, implicating BZDs as pathogenetic factors, has been provided (11). Indeed, a unifying concept relating to the pathogenesis of HE considered that ammonia contributes to this syndrome by directly potentiating inhibitory GABAergic neurotransmission. Endogenous BZDs may potentiate inhibitory GABAergic neurotransmission by acting synergistically with ammonia (12, 13).

To evaluate the possible correlation between ammonia and BZDs in the pathogenesis of HE, we assayed venous ammonia and BZD plasma levels in patients with liver cirrhosis with different impairment of the liver function and with different degree of HE, free of commercial BDZ drugs.

Materials and Methods

We assayed venous ammonia and BZD plasma levels in 58 liver cirrhosis (34 male, 24 female), free of commercial BZD drugs. The patients, evaluated clinically and on the basis of electroencephalographic pattern, were divided into the following groups: 34 cases degree 0, 4 degree I, 7 degree II, 5 degree III and 8 degree IV. Regarding the liver function, the patients were classified according to the Child-Pugh classification: Child A 15, B 18, C 25 patients. The study was a

retrospective analysis and cases with overt precipitating factors such as bleeding were excluded.

Ammonia was assayed in sera by standard colorimetric test (Ammonia test Kit II, Menarini diagnostics, Florence, Italy).

Quantification of BZDs was performed as previously described (7, 14). Aliquots of all the serum samples (1 ml) were acidified with acetic acid (1 M) and centrifuged at $3000 \times g$ for 10 min. The supernatant was passed through previously washed Sep-Pak C_{18} cartridges (Millipore, Medford, MA, U.S.A.). The material was eluted from Sep-Pak with $CH_3CN/0.1\%$ trifluoroacetic acid (TFA) and then lyophilized. The lyophilized samples were reconstituted with 1 ml H_2O and aliquots (200 μ l) were chromatographed in duplicate at 0.8 ml/min on a LiChrospher 100 RP-18 column (250×4.0 mm; 5 μ m) equilibrated with 80% water/0.1% trifluoroacetic acid and 20% acetonitrile. Absorbance was monitored at 230 nm. Samples were chromatographed using a water/0.1% TFA and acetonitrile gradient at 0.5%/min from 20% to 58% acetonitrile. Seventy-five fractions (1/min) from each sample were collected, lyophilized and reconstituted with water before radioreceptor assay. Known concentrations of diazepam, N-desmethyldiazepam, oxazepam, lorazepam, delorazepam and 2'-chlordiazepam were run in parallel with the plasma samples.

Unless otherwise indicated, all reagents were obtained from Sigma Chemical Co. and were all HPLC grade. All the fractions were then tested for their ability to inhibit [3H]flunitrazepam (1 nM, specific activity 87 Ci/mmol, NEN, Boston, MA, U.S.A.) binding to rat cerebellar membrane preparations (180–200 μ g protein/100 μ l measured by Bradford's method). Data were expressed as diazepam equivalents (DE) based on extrapolation from standard displacement curves generated using diazepam. The total concentrations of BDZ-like compounds present in each serum were calculated by determining the DE derived from the displacement activity of any single peak and then summing the amount of values of all peaks. Since the chemical identity of all components of the BDZ-like material are unknown, their extraction efficiencies could not be determined. The limit of detection of diazepam by [3H]flunitrazepam binding was 2 nmol DE/L with a coefficient variation of 0.52. The assays were done in triplicate and variations from the mean were less than 15%.

Values of BDZs and ammonia were analysed using the Kolmogorov-Smirnov test. Comparisons of BDZs and ammonia between the Child-Pugh classes and HE degrees were performed by ANOVA. With α set to 0.05, the employed sample size ensured a power of 0.99 and 0.90 for BDZ comparisons in the HE and Child-Pugh groups, respectively. Corresponding values for ammonia were 0.88 and 0.71. Linear regression was used to test the hypothesis that BDZ levels have the tendency to increase with increasing levels of ammonia (residuals were normally distributed). Statistical analysis was performed on a MacOS computer using the Statview 5.0 software package.

Results

The values of BZDs and ammonia in cirrhotic patients classified according to Child-Pugh score are, respectively: [geometric mean (minimum value–maximum value)] Child A 17 (2–701) and 38 (12–154); Child B 111 (2–4019) and 67 (4–235); Child C 238 (2–3508) and 73 (14–410) (BZDs and ammonia in Child A versus B and C: $P < 0.05$). The values of BZDs and ammonia in cirrhotic patients classified according to the degree of HE (0, I and II; III and IV) are, respectively: [geometric mean (minimum value–maximum value)] degree 0 35 (2–820) and 47 (12–235); degrees I and II 183 (2–4019) and 72 (14–145); degrees III and IV 770 (2–3508) and 100 (21–410) (BZDs and ammonia in degree 0 versus degree III and IV: $P < 0.05$). On the pooled samples, there is no correlation between BZDs and ammonia levels ($R = 0.275$), indicating that the increase in BZDs is independent of the increase in ammonia levels (see Fig. 1). No statistical differences between age and sex were found.

Conclusions

We have shown in this study, which includes fully characterized liver cirrhotic patients, that BZD levels rise in the serum of cirrhotic patients in proportion to the worsening of the liver function, but not to the degrees of HE and levels of ammonia.

The finding that encephalopathy may occur in liver cirrhotic patients with low levels of circulating BZD-like compounds is in line with the results of previous studies of patients with HE due to fulminant hepatic failure (15), and support the concept that BZDs rather than pathogenetic agents




Fig. 1. Regression analysis between benzodiazepine (BZD) and ammonia (NH_4) levels in serum of patients with liver cirrhosis.

seem to be precipitating factors of HE. In fact, while in non-cirrhotic patients there is tolerance to BZD chronic exposure, in patients with liver cirrhosis there is an increased cerebral response to BZDs owing to the occurrence of a supersensitivity phenomenon of the GABA_A receptor. Hence, it seems fair to surmise that the enhanced GABAergic tone cannot be attributed to an increased presence of endogenous BZD-like compounds 'per se', but more likely to the presence of pre-existing brain dysfunction related, for example, to ammonia toxicity (1, 16, 17). An accumulation of endogenous compounds with sedative action may occur in patients with liver cirrhosis during the course of the disease independently from HE. These compounds may be more effective only in patients with a pre-existing altered brain function (18, 19).

In conclusion, these data point to the lack of a synergistic effect of ammonia and BZDs in the pathogenesis of HE and underline again the importance of distinguishing between primary and secondary events in the development of HE.

References

- Zeneroli ML. Hepatic encephalopathy. Experimental studies in a rat model of fulminant hepatic failure. *J Hepatol* 1985;1:301–12.
- Jones EA, Skolnick P, Gammal H, Basile AS, Mullen KD. The gamma-aminobutyric acid-A (GABA-A) receptor complex and hepatic encephalopathy. Some recent advances. *Ann Intern Med* 1989;110:532–46.
- Schafer DF, Jones EA. Hepatic encephalopathy and the γ -aminobutyric acid neurotransmitter system. *Lancet* 1982;i:18–20.
- Baraldi M, Zeneroli ML, Ventura E, Penne A, Pinelli G, Ricci P, et al. Supersensitivity of benzodiazepine receptors in hepatic encephalopathy due to fulminant hepatic failure in the rat: reversal by benzodiazepine antagonist. *Clin Sci* 1984;67:167–75.
- Scollo-Lavizzari G, Steinmann E. Reversal of hepatic coma by benzodiazepine antagonist (Ro 15–1788). *Lancet* 1985;1:1324.
- Bansky G, Meier PJ, Ziegler WH, Walser H, Schmid M, Huber M. Reversal of hepatic coma by benzodiazepine antagonist (Ro 15–1788). *Lancet* 1985;1:1324–5.
- Avallone R, Zeneroli ML, Venturini I, Corsi L, Schreier P, Kleinschnitz M, et al. Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of patients with liver cirrhosis with and without overt encephalopathy. *GUT* 1998;42:861–7.
- Basile AS, Harrison PM, Hughes RD, Gu ZQ, Pannell L, McKinney A, et al. Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. *Hepatology* 1994;19:112–21.
- Ferenci P, Grimm G, Meryn S, Gangl A. Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil. *Gastroenterology* 1998;96:240–3.
- Barbaro G, DiLorenzo G, Soldini M, Giancaspro G, Bellomo G, Belloni G, et al. Flumazenil for hepatic encephalopathy grades III and IVa in patients with cirrhosis: an Italian multicenter double-blind placebo-controlled cross-over study. *Hepatology* 1998;28:374–8.
- Blei AT, Butterworth RF. Hepatic encephalopathy. *Semin Liver Dis* 1996;16:233–9.
- Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. *Hepatology* 1997;25:1303–305.
- Mullen KD, Jones EA. Natural benzodiazepines and hepatic encephalopathy. *Semin Liver Dis* 1996;16:255–64.
- Olasmaa M, Rothstein JD, Guidotti A, Weber PJ, Paul SM, Spector S, et al. Endogenous benzodiazepine in human and animal hepatic encephalopathy. *J Neurochem* 1990;55:2015–23.
- Zeneroli ML, Venturini I, Corsi L, Avallone R, Farina F, Ardizzone G, et al. Benzodiazepine-like compounds in the plasma of patients with fulminant hepatic failure. *Scand J Gastroenterol* 1998;33:310–3.
- Baraldi M. Supersensitivity of GABA-A receptors in hepatic encephalopathy. *Neurochem Res* 1990;15:153–60.
- Itzhah Y, Norenberg MD. Ammonia-induced up-regulation of peripheral-type benzodiazepine receptors in cultured astrocytes labeled with [3H]PK11195. *Neurosci Lett* 1994;177:35–8.
- Branch RA, Morgan MH, James J, Read AE. Intravenous administration of diazepam in patients with chronic liver disease. *Gut* 1976;17:975–83.
- Baktir GA, Fisch HU, Karlaganis G, Minder C, Bircher J. Mechanism of the excessive sedative response of cirrhotics to benzodiazepine: model experiments with triazolam. *Hepatology* 1987;7:629–38.

Received 10 July 2000

Accepted 9 October 2000